Medicinal product containing palivizumab

Summary

The tender concerns the supply of a medicinal product containing palivizumab active substance for healthcare use. Palivizumab is a recombinant humanized monoclonal antibody used to prevent severe respiratory syncytial virus disease in high-risk children. The contract covers up to 1200 doses with an estimated total value of EUR 352,332. Offers must be submitted electronically; the tender validity is four months and the planned contract duration is 24 months. The procurement is SME-friendly. Detailed requirements and documentation must be checked in the tender documents.